A Phase 1 interventional study of ALXN1210 SC and ALXN1210 IV in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-01.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the safety and tolerability of a single dose of ALXN1210 subcutaneous (SC) compared to ALXN1210 intravenous (IV) in healthy participants and to determine the absolute bioavailability of ALXN1210 SC.
The participants were randomly assigned in a 2:1 ratio to Cohort 1a in a blinded fashion to receive either a single dose of ALXN1210 SC 400 mg or single dose of placebo SC. The Safety Review Committee (SRC) evaluated the first 48 hours of postdose clinical safety data for participants in Cohort 1a to determine if enrollment into Cohorts 1b or 2 could begin. Following the SRC review, participants were randomly assigned in a 2:1 ratio to either Cohort 1b or Cohort 2. Within Cohort 1b, participants were blinded and further randomly assigned in a 5:1 ratio to receive either a single dose of ALXN1210 SC 400 mg or a single dose of placebo SC, respectively. The participants in Cohort 2 received a single dose of ALXN1210 IV 400 mg in an open-label fashion. Safety, PK, PD, and immunogenicity assessments were performed on the follow-up period after the last dose.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ALXN1210 SC.
Drug: ALXN1210 SC
Participants received ALXN1210 IV.
Drug: ALXN1210 IV
Participants received placebo SC.
Drug: Placebo
All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
Also known as: Ravulizumab, Ultomiris
All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
Also known as: Ravulizumab, Ultomiris
All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs with a start date or time on or after the first dose of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline up to Day 200
Absolute Bioavailability of ALXN1210 SC
The absolute bioavailability of ALXN1210 SC is reported as the area under the serum concentration versus time curve from time 0 extrapolated to infinity (AUCinf) geometric mean of the ALXN1210 SC group divided by the AUCinf geometric mean of the ALXN1210 IV group\*100. Linear mixed model with fixed and random effects for the participant was used.
Time frame: Predose , end of infusion (EOI); 30 minutes post EOI; 2, 4, and 8 hours post start of infusion; and from Day 2 up to Day 150
Percent Change From Baseline in Free Complement Protein C5 Concentration At Day 8
Blood samples were collected to determine the percent change in free C5 serum concentration from baseline over time.
Time frame: Baseline, Day 8
Percent Change From Baseline In Chicken Red Blood Cell Hemolysis At Day 8
Blood samples were collected to determine the percent change in cRBC from baseline over time.
Time frame: Baseline, Day 8
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
Blood samples were collected to evaluate antibody response through development of ADAs. The number of participants who developed ADAs (ADA positive) to ALXN1210 were reported in this outcome measure.
Time frame: Baseline up to Day 200
| Milestone | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC |
|---|---|---|---|
| Started | 24 | 12 | 6 |
| Received at least 1 dose of study drug | 24 | 12 | 6 |
| Completed | 24 | 12 | 6 |
| Not completed | 0 | 0 | 0 |
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs with a start date or time on or after the first dose of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 19 | 11 | 5 |
The absolute bioavailability of ALXN1210 SC is reported as the area under the serum concentration versus time curve from time 0 extrapolated to infinity (AUCinf) geometric mean of the ALXN1210 SC group divided by the AUCinf geometric mean of the ALXN1210 IV group\*100. Linear mixed model with fixed and random effects for the participant was used.
| percentage of ratio | ALXN1210 400 mg SC/IV |
|---|---|
| Absolute Bioavailability of ALXN1210 SC | 60.4 (49.7 to 73.3) |
Blood samples were collected to determine the percent change in free C5 serum concentration from baseline over time.
| percent change | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC |
|---|---|---|---|
| Percent Change From Baseline in Free Complement Protein C5 Concentration At Day 8 | -77.08 ± 24.481 | -98.81 ± 0.707 | 6.40 ± 13.397 |
Blood samples were collected to determine the percent change in cRBC from baseline over time.
| percent change | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC |
|---|---|---|---|
| Percent Change From Baseline In Chicken Red Blood Cell Hemolysis At Day 8 | -29.49 ± 33.278 | -66.72 ± 33.553 | -11.14 ± 9.330 |
Blood samples were collected to evaluate antibody response through development of ADAs. The number of participants who developed ADAs (ADA positive) to ALXN1210 were reported in this outcome measure.
| Participants | ALXN1210 400 mg SC | ALXN1210 400 mg IV |
|---|---|---|
| Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210 | 3 | 1 |
Collected over Baseline up to Day 200. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ALXN1210 400 mg SC | 0/24 (0%) | 0/24 (0%) | 19/24 (79.2%) |
| ALXN1210 400 mg IV | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Placebo SC | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/24 | 7/12 | 5/6 |
| HeadacheNervous system disorders | 1/24 | 3/12 | 3/6 |
| Vulvovaginal candidiasisInfections and infestations | 0/8 | 0/4 | 1/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/24 | 2/12 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/24 | 1/12 | 1/6 |
| NauseaGastrointestinal disorders | 0/24 | 1/12 | 1/6 |
| Lower respiratory tract infectionInfections and infestations | 1/24 | 0/12 | 1/6 |
| GastroenteritisInfections and infestations | 0/24 | 0/12 | 1/6 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/24 | 1/12 | 0/6 |
| MigraineNervous system disorders | 2/24 | 1/12 | 0/6 |
The safety population consisted of all participants who received the protocol-defined, single dose of study drug (ALXN1210 IV, ALXN1210 SC, or placebo SC).
| Age, Continuous(years) | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC | Total |
|---|---|---|---|---|
| Mean | 36.2 ± 7.73 | 33.2 ± 8.20 | 34.2 ± 6.46 | 35.0 ± 7.65 |
| Sex: Female, Male(Participants) | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC | Total |
|---|---|---|---|---|
| Female | 8 | 4 | 2 | 14 |
| Male | 16 | 8 | 4 | 28 |
| Ethnicity (NIH/OMB)(Participants) | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 23 | 11 | 6 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | ALXN1210 400 mg SC | ALXN1210 400 mg IV | Placebo SC | Total |
|---|---|---|---|---|
| Asian | 2 | 2 | 1 | 5 |
| Black or African American | 5 | 0 | 1 | 6 |
| White | 17 | 10 | 2 | 29 |
| Other | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Clinical study report
Ran from Aug 2016 to primary completion in Jul 2017, 10 months.
Results were first posted in May 2023, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →